Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion

Circulation

Volumn 93, Issue 3, 1996, Pages 544-551

  Piana, Robert N ^a   Wang, Steven Y ^a   Friedman, Menachem ^a   Sellke, Frank W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

arteries; enzymes; microcirculation; reperfusion

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; CALCIMYCIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; NITROPRUSSIDE SODIUM;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HEMODYNAMIC MONITORING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SWINE;

EID: 0030023138     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.3.544     Document Type: Article

References (42)

1. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, for the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS). N Engl J Med. 1992;327:678-684.
2. Nabel EG, Topol EJ, Galeana A, Ellis SG, Bates ER, Werns SW, Walton JA, Muller DW, Schwaiger M, Pitt B. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol. 1991;17:467-473.
3. Gruppo Italiano per lo Studio della Sporawivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343: 1115-1122.
4. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995; 345:669-685.
5. Li K, Chen X. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Moll Cell Cardiol. 1987;19:909-915.
6. Ehring T, Baumgart D, Krajcar M, Hummelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation. 1994;90:1368-1385.
7. de Graeff PA, van Gilst WH, Bel K, de Langen CDJ, Kingma JH, Wesseling H. Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model. J Cardiovasc Pharmacol. 1987;9:S37-S42.
8. Przyklenk K, Kloner RA. Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemia/reperfusion injury. Br J Clin Pharmacol. 1989;28: 167S-175S.
9. Chilian WM, Eastham CL, Marcus ML. Microvascular distribution of coronary vascular resistance in beating left ventricle. Am J Physiol. 1986;251:H779-H788.
10. Nellis SA, Liedtke AJ, Whitesell L. Small coronary vessel pressure and diameter in an intact beating heart using fixed position and tree motion techniques. Circ Res. 1981;49:342-353.
11. Kloner RA, Ganote CE, Jennings RB. The 'no-reflow phenomenon following temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508.
12. Schoffer J, Montz R, Mathey D. Scintigraphic evidence of the 'no-reflow' phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol. 1985;5:593-598.
13. Ito H, Tomooka T, Sakai N, Higashino Y, Fujii K, Masuyama T, Kitabatake A, Minamino T. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85:1699-1705.
14. Quillen JE, Sellke FW, Brooks LA, Harrison DG. Ischemia-reperfusion impairs endothelium-dependent relaxation of coronary microvessels but does not affect large arteries. Circulation. 1990;82: 586-594.
15. Ku DD. Coronary vascular reactivity after myocardial ischemia. Science. 1982;218:576-578.
16. Piana RN, Shafique T, Dai HB, Sellke FW. Epicardial and endocardial coronary microvascular responses: effects of ischemia-reperfusion. J Cardiovasc Pharmacol. 1994;23:539-546.
17. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
18. Ferrari R, Cargnoni A, Curello S, Ceconi C, Boraso A, Visioli O. Protection of the ischemic myocardium by the converting enzyme inhibitor zofenopril: insight into its mechanism of action. J Cardiovasc Pharmacol. 1992;20:694-704.
19. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol. 1993;234:229-236.
20. van Wijngaarden J, Tobe TJM, Weersink EGL, Bel KJ, de Graeff PA, de Langen CDJ, van Gilst WH, Wesseling H. Effects of early angiotensin converting enzyme inhibition in a pig model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol. 1992;19: 408-416.
21. Rosen P, Eckel J, Reinauer H. Influence of bradykinin on glucose uptake and metabolism studied in isolated cardiac myocytes and isolated perfused rat hearts. Hoppe Seylers Z Physiol Chem. 1983; 364:1431-1438.
22. Farber HW, Center DM, Rounds S, Danilov SM. Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur Heart J. 1990;11:B-100-B-107.
23. Rubanyi GM, Ho EH, Cantor EH, Lumma WC, Parker Botelho LH. Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun. 1991;181:1392-1397.
24. Weyrich AS, Ma XL, Lefer AM. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation. 1992;86:279-288.
25. Dinerman JL, Lowenstein CJ, Snyder SH. Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease. Circ Res. 1993;73:217-222.
26. Schror K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20:S68-S73.
27. Radomski NW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;338:1057-1058.
28. Furlong B, Henderson AH, Lewis MJ, Smith JA. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol. 1987;90:687-692.
29. Linz W, Wiemer G, Scholkens BA. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol. 1992;24:909-919.
30. Sellke FW, Shafique T, Ely DL, Weintraub RM. Coronary endothelial injury after cardiopulmonary bypass and ischemic cardioplegia is mediated by oxygen-derived free radicals. Circulation. 1993;88(suppl II):II-395-II-400.
31. Dauber IM, Lesnefsky EJ, VanBethuysen KM, Weil JV, Horwitz LD. Reactive oxygen metabolite scavengers decrease functional coronary microvascular injury due to ischemia-reperfusion. Am J Physiol. 1991;260:H42-H49.
32. Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation. 1988;77(suppl I):I-30-I-39.
33. Bagchi D, Prasad R, Das DK. Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem Biophys Res Commun. 1989;158:52-57.
34. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensin-converting enzyme inhibitors: free radical and oxidant scavenging are sulfhydryl dependent but lipid peroxidation is inhibited by both sulfhydryland nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Phamacol. 1992;19:330-340.
35. Gillis CN, Chen X, Merker MM. Lisinopril and ramiprilat protection of the vascular endothelium against free radical-induced functional injury. J Pharmacol Exp Ther. 1992;262:212-216.
36. Liao DF, Chen X. Prostacyclin-mediated protection by angiotensin-converting enzyme inhibitors against injury of aortic endothelium by free radicals. Cardioscience. 1992;3:79-84.
37. Mehta JL, Nicolini FA, Lawson DL. Sulfhydryl group in angiotensin converting enzyme inhibitors and superoxide radical formation. J Cardiovasc Pharmacol 1990;16:847-849.
38. Kukreja RC, Kontos HA, Hess ML. Captopril and enalaprilat do not scavenge the superoxide anion. Am J Cardiol. 1990;65:24I-27I.
39. Chilian WM, Layne SM, Klausner EC, Eastham CL, Marcus ML. Redistribution of coronary microvascular resistance produced by dipyridamole. Am J Physiol. 1989;256:H383-H390.
40. Lefer DJ, Nakanishi K, Vinten-Johansen J, Ma XL, Lefer AM. Cardiac venous endothelial dysfunction after myocardial ischemia and reperfusion in dogs. Am J Physiol. 1992;263:H850-H856.
41. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J. 1991;121:1319-1330.
42. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med. 1991;42:225-246.